The purpose of this study was to evaluate the safety and efficacy of Movicol in the treatment of chronic constipation in children.
Official Title
An Open Single Centre Study To Assess the Safety and Efficacy of Movicol in the Treatment of Chronic Constipation in Children
Conditions
Chronic Constipation
Study Type
Interventional
Study Design
Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety/Efficacy Study
Further Details
Primary Outcome Measures:
- The average number of spontaneous complete defaecations per week recorded over the period of treatment between scheduled visits.
Secondary Outcome Measures: Assessment of:
- abdominal pain
- amount of stool
- faecal form (Bristol stool scale)
- rectal bleeding
- pain on defaecation
- straining on defaecation
- stool withholding
- faecal incontinence (soiling)
- efficacy (investigator and parental assessment)
- concomitant laxative treatment
All patients were screened at Day 0 (Visit 1) when baseline assessment of their bowel movements over the previous 14 days were made. Patients were dispensed with Movicol to commence treatment on the following day (Day 1). During the first 5 days the dose was increased on an every second day basis until normal bowel movement was achieved. Thereafter until the end of the study the dosage was titrated according to the stool consistency (diarrhoea, loose stool, hard stools or no bowel movement for 2 days, respectively). Four on-treatment visits were performed on Day 14 (Visit 2), Day 28 (Visit 3), Day 56 (Visit 4) and Day 84 (Visit 5). At each visit bowel movements over the preious period were assessed by the investigator using the patient’s daily diary card data.
Study Start
August 2001; Study completion: January 2003
Eligibility & Criteria
- Ages Eligible for Study: 24 Months – 11 Years
- Genders Eligible for Study: Both
Inclusion Criteria:
- children aged 24 months – 11 years old inclusive
- patients with constipation defined as < 2 spontaneous complete bowel movements per week (over the previous 14 days), and one or more of the following:
- 1/4 or more of bowel movements with straining
- 1/4 or more of bowel movements with hard or lumpy stools
- patients in whom these symptoms have been present for > 3 months
- new patients or those whose management is unsatisfactory on current laxative treatment
- patients of either sex
- patients of any ethnic origin
- hospital in-patients or outpatients.
Exclusion Criteria:
- history of bowel washout within the last 2 months
- intestinal perforation or history of obstruction
- recent history of urinary tract infection (within last month)
- Hirschsprungs disease
- paralytic ileus
- toxic megacolon
- severe inflammatory conditions of the intestinal tract
- clinically uncontrolled renal/hepatic/cardiac disease(s)
- clinically uncontrolled endocrine disorder(s)
- any other severe unstable co-existing disease
- hypersensitivity to macrogol or other constituents of Movicol
- encopresis
- patients who have taken any investigational drug in the last three months
- patients or patients whose parents would in the opinion of the investigator be unable to comply with the requirements of the study.
Total Enrolment
100
Contact Details
Royal Children’s Hospital, Parkville, Victoria, 3052, Australia
- Winita Hardikar, MD, Principal Investigator, Royal Children’s Hospital
All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.